Review Article

Performance evaluation of antimicrobial peptide ll-37 and hepcidin and β-defensin-2 secreted by mesenchymal stem cells

Reza Esfandiyari a, Raheleh Halabian a, Elham Behzadi b, Hamid Sedighian a, Ramezan Jafari c, Abbas Ali Imani Fooladia,*

a Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
b Department of Microbiology, College of Basic Sciences, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran
c Department of Radiology, Baqiyatallah University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Keywords:
Biotechnology
Microbiology
Molecular biology
Proteins
Infectious disease
Mesenchymal stem cells
Antimicrobial peptides
Bacteria

ABSTRACT

Peptides are secreted by different cell types and are trendy therapeutic agents that have attracted attention for the treatment of several diseases such as infections. Antimicrobial peptides exert various mechanisms such as changing cell membrane permeability which leads to inhibition or death of bacterial cells. mesenchymal stem cells (MSCs) are key to produce antimicrobial peptides and to inhibit the growth of pathogens. These cells have been shown to be capable of producing antimicrobial peptides upon exposure to different bacteria. As a result, antimicrobial peptides can be considered as novel agents for the treatment of infectious diseases. The purpose of this review was to investigate the targets and mechanisms of antimicrobial peptides secreted by MSCs.

1. Introduction

Antibiotics are used to treat bacterial infections through either inhibiting or killing the target bacteria. The first antibiotic was discovered by Alexander Fleming in 1928, called penicillin and saved the lives of millions of people. However, the discovery of penicillin as a modern medication was preceded by the management of microbial infections in Egypt, Greece and ancient China [1]. Shortly after the discovery of penicillin, the bacterial resistance to this antibiotic became one of the challenges in the treatment of bacterial infections. Therefore, new generation of beta-lactam antibiotics was developed to overcome antibiotic resistance and to treat bacterial infections. However, the first case of methicillin-resistant Staphylococcus aureus (MRSA) was reported in England in 1962 [2,3]. The production and discovery of new antibiotics continue to this day and new antibiotics are marketed to counteract the drug resistance problem. Yet, the point should be raised that one day antibiotics can no longer affect bacteria and will no longer be able to control bacterial infections. Consequently, in recent years, researchers have devised other means to treat bacterial infections. One of such approaches is the use of antimicrobial peptides (AMPs) or “peptide antibiotics” to kill pathogenic bacteria and to treat bacterial infections [4]. Over the past decades, antimicrobial peptides (peptide antibiotics) have been shown to be effective in innate immunity of various species, such as plants, invertebrates and vertebrates.

The intrinsic immune system is the first line of defense against the attack of microorganisms, among which the antimicrobial peptide molecules are the most important ones. The cathelicidin family is important antimicrobial agents in mammals [5, 6]. These peptides are mainly stored in lysosomes of macrophages (MQ) and polymorphonuclear neutrophils (PMNs) [7]. Cathelicidins have been isolated from many cell types including neutrophils to coordinate the immune system, but have been found in other immune cells such as epithelial cells and macrophages and have been shown to combat against bacteria, viruses and fungi. Cathelicidins have a variety of sizes (12–80 amino acids) and also have a wide range of structures [8]. The molecular mechanism of antimicrobial peptides has been investigated [9]. Stem cells have been the focus of research because they have shown good potential in the field of therapy [10]. One of the features of the stem cells referred to in this review is antimicrobial activity of mesenchymal stem cells that perform this action through antimicrobial peptides such as ll-37, Hepcidin and β-Defensin-2 [11]. The purpose of this study is to briefly review mesenchymal stem cells and antimicrobial peptides and how these peptides function.

* Corresponding author.
E-mail address: imanifouladi.a@gmail.com (A.A. Imani Fooladi).

https://doi.org/10.1016/j.heliyon.2019.e02652
Received 23 July 2019; Received in revised form 2 September 2019; Accepted 9 October 2019
2405-8440/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Main text

2.1. Mesenchymal stem cells (MSCs)

In recent years, stem cells have been widely used in the treatment of many diseases. One of the most important stem cells is mesenchymal stem cells (MSCs) that have been shown to play a role in regulating the immune system and suppressing deleterious properties. MSCs have the ability to differentiate into mesenchymal tissues such as cartilage, bone, muscle and fat. MSCs have been obtained from bone marrow, umbilical cord, blood, placenta, skeletal muscle and adipose tissue. Recent studies have found that MSCs play an important role in the treatment of diseases, including infections, by producing antimicrobial peptides [12, 13, 14].

2.2. Antimicrobial peptides (AMP)

Cathelicidin is a carrier that has a wide range of functional molecules (i.e. cysteine or non-cysteine). The presence of this peptide has been proven in cattle, rabbits, pigs and humans [15].

Due to the unique characteristics of antimicrobial peptides, these peptides are one of the main candidates in the treatment of bacterial diseases and are effective on antibiotic resistant strains and even cancer cells. These properties include rapid killing and a wide range of activity that perform antimicrobial action by pore-forming the cell membrane [16]. But these peptides can also be toxic to the cells of the body, so using peptides with a wide range of lethality and low side effects can help cure bacterial infections [17].

2.3. LL-37 antimicrobial peptides

In 1995, Agerberth et al [18] based on the protected section of cathepsin, derived human bone marrow cDNA clones from an unspecified antibacterial peptide named FA-LL-37. The peptide constitutes of 39
amino acids whose N-terminal is FALL and the name of the peptide was coined for FALL. The helical structure of this peptide was investigated in a saline environment containing vitamin E upon synthesis and antibacterial activity was investigated [9]. The peptide is specifically secreted in the secondary granules of neutrophils. It is also produced by many types of cells, including macrophages, natural killer (NK) cells, epithelial cells of the skin, airways, eyes and intestinal tract. Also, the expression of the peptide LL-37 is controlled by inflammatory pathways, similar to the pathway of vitamin D [19].

In addition to antimicrobial activity, this peptide has immunomodulatory roles. For example, exposure to 10 μg/ml of LL-37 peptide during a monocyte-macrophage differentiation leads to a positive inflammatory response, resulting in a decrease in the level of interleukin 10 and an adjustment of 12p40. In addition, the peptide LL-37 leads to the phenotype M1, which suggests that this peptide has an important role in the development of macrophages and cytokine production [20].

Other chemical properties of LL-37 is as follows: migration of neutrophils and eosinophils through the formyl-peptide receptor; transactivation of the epidermis growth factors by the peptide causes the migration of keratinocytes, which results in wound healing; MCP-1CCL-2 is a monocyte extraction factor that is secreted by LL-37 after stimulation. In addition, transforming growth factor beta (TGFβ) released from the epithelial cells of the intestine after exposure to LL-37 has an effect on the migration of epithelial cells and improved response. It is concluded that the peptide LL-37 is spread at the site of the infection, causing inflammatory response and wound healing [20, 21, 22].

LL-37 peptide has different activities, all of which lead to antimicrobial activity. These include regeneration and angiogenesis, which is done by the formyl-peptide receptor-like 1 expressed on the endothelial cells [23]. Chemotaxis is also one of the activities of this peptide, which causes the migration of mast cells to the environment [24]. In addition, degranulation of mast cells and the release of inflammatory mediators takes place by the LL-37 peptide [25]. LL-37 peptide, on the other hand, induces many cytokines and induces the production of antibodies [26]. LL-37 peptide from primary human keratinocytes and human keratinocytes (HaCaT) cells protect from apoptosis [27]. The results have shown that fluid membrane-associated peptides increases the plasma membrane of the subcutaneous glandular cells [28]. This peptide also considered as an endotoxin, which inhibits the responses of inflammatory proteins to the bacterial lipopolysaccharides (LPS) in human cells (Fig. 1) [29].

2.4. LL-37 peptide function

This peptide performs its actions by connecting to cell receptors (Table 1). As previously mentioned, LL-37 is actively involved in physiological responses to eukaryotic cells, which is essentially an antimicrobial peptide. This peptide is effective in people whose immune system is low, so that through transactivation of EGFR and angiogenesis by FPRL1 receptor and chemotaxis causes cell migration [30].

In addition, the expression of transgenic LL-37 leads to a significant increase in proliferation of corpuscular cells in HaCaT and HEK 293 [33]. With the presence of lymph node metastases in estrogen-receptor positive or ER positive cancer, clinical trials have shown an increase in Erb-B2 receptor tyrosine kinase 2 (ERBB2) signaling, indicating an increase in peptide LL-37 activity, which plays an important role in the treatment of cancer [34].

This peptide also interacts with P2X7 purinoceptor, which is expressed mainly in monocytes, macrophages and dendritic cells (DCs) and stimulates and releases cytokine IL-1β in human gingival fibroblasts (Fig. 2) [35]).

---

Fig. 3. Hepcidine structure. Structure of the human hormone hepcidin (top panel) and the portion used for the minihepcidin design (bottom panel) [38].

Fig. 4. After expressing the hepcidin in the cell, ferritin is transmitted to the macrophage and is degraded by lysozyme, resulting in the storage of iron inside the cell [40, 51].
2.5. Human antimicrobial peptide hepcidin

Another antimicrobial peptide produced by MSCs is hepcidin, which plays an important role in the clearance of pathogens. This antimicrobial peptide is rich in cysteine, the precursor of which is secreted by the liver (Fig. 3). Hepcidin is present in three forms of prohormone (84 amino acids), prohormone (60 amino acids) and hormones (25 amino acids) [36]. This peptide was discovered in 2000 and was called LEAP 1, but after a while due to presence in the liver, the peptide was named “hepcidin”. This peptide is effective on a wide range of fungi, bacteria and viruses. One of the most important effects of hepcidin in the body is the regulation of iron hemostasis. This peptide prevents iron absorption from the small intestine and releases iron from reticuloendothelial cells. In infectious diseases, macrophages and bacteria compete to absorb iron [37]. Macrophages interfere with the absorption of iron by bacteria. Eventually, the pathogen does not grow and replenish. Factors that cause hepcidin production are increased in bone marrow and anemia. Other factors that increase the production of hepcidin are iron accumulation and inflammation [38].

2.6. Mechanism of hepcidin

Hepcidin is effective on iron transfer from macrophages. In the presence of hepcidin, ferritin is transmitted into the macrophage and is destroyed by lysosomes, resulting in storage of iron inside the cell. In low concentrations of hepcidin, ferritin is present in the cell membrane, allowing the release of iron. After leaving the cell, iron oxide is rapidly oxidized by ceruloplasmin, a copper-rich ferroxidase and converted into ferric iron and then bound to transferrin [39].

Hepcidin is bound to plasma alpha-2 macroglobulin (alpha 2M). Evidence suggests that other cells may express the hepcidin mRNA at a much lower level than the hepatocytes; the biological significance of the extra hepatic production of hepcidin remains uncertain. Plasma hepcidin is freely treated through glomeruli and in animals with normal kidney activity it quickly passes through the urine. In addition, a part of hepcidin is cleansed through degradation along with ferritin [40] (Fig. 4).

2.7. Defensins

Cysteine-rich cationic proteins are found in vertebrates, invertebrates and plants, which range from 18 to 145 amino acids [41]. The role of these peptides is to defend the host against bacteria, fungi and viruses. These peptides play a role in destroying the bacterial cell membrane. Defensins were discovered for the first time in 1980. The basic genes produced by these peptides are highly polymorphic. Generally, defensins are classified in three main groups of alpha, beta and theta, each of which has different genetic symbols and is produced from different cells [42], as shown in Table 2.

In immature individuals, defensins (present in breast milk) play a very important role in protecting the disease due to the weak immune system. The Defensin is produced by epithelial cells and leukocytes, as indicated in Table 2. Alpha defensin exists only in mammals, while beta defensin exists only in humans and other primates.

R. Esfandiyari et al. Heliyon 5 (2019) e02652

4
defensin has been found in several species of ancient monkeys, but not in humans and other primates. The important point is that the mRNA manages to denote the theta defensin, but the mutations cause the end codon to stop peptide production. One of the key characteristics of defensin is their antimicrobial activity, which is active against Gram-positive and Gram-negative bacteria, fungi and viruses [46].

In addition to antimicrobial activity, defensin exerts other functions that includes chemical absorption for monocytes, cytokines production by monocytes and epithelial cells, angiogenesis activity and response to hormones. Antimicrobial effect on Gram-positives is different from Gram-negative bacteria. The reason is that, first, the cell wall structure of Gram-positive bacteria is different from Gram-negatives (the cell wall of Gram-negative bacteria is rich in lipopolysaccharide (LPS), which has a negative charge, while in Gram-positive bacteria the cell wall have teichoic acids (TA) with less negative charge. Secondly, the peptidoglycan layer is thick in Gram-positive bacteria and the formation of pores by defensin on the surface of the Gram-positive requires more time. Therefore, defensin has weaker anti-microbial activity in Gram-positive bacteria [46].

Defensin functions on the bacterial cells via the L-arginine cationic chain that are attached by electrostatic absorption to the membrane’s anionic structure, then defensin is introduced into the membrane by using the electromotive force of the membrane, creating channels inside the membrane. Ultimately, materials that are surrounded by membranes are leaked outside or inside the cell and causes bacterial cell lysis [46].

2.8. The role of MSCs in destroying pathogenic bacteria

Attempts to design novel treatment strategies as alternatives for the current treatment of diseases such as sepsis, bacteremia, bloodstream infections and other bacterial infections have become a major challenge. One of the most important treatments used to kill pathogenic bacteria is the use of antibiotics, which has some disadvantages in addition to its benefits. Antibiotic resistance is one of the biggest treatment problems with antibiotics. Antibiotic resistance is on the rise and the number of resistant are constantly circulating in the communities and it can be said that it will not last long as antibiotics will no longer be effective against bacteria [47, 48]. An emerging approach to treat infections is the use of antimicrobial peptides produced from various cells, including MSCs. Research has shown that MSCs have antimicrobial properties and this property is related to the production of antimicrobial peptides (Fig. 5) [14].

There are several barriers to using stem cells in treatment, such as the immune response to stem cells that can reduce the function of these cells, as well as their use may cause infection, poisoning, cancer and even death [49]. As a result, it is better to use mesenchymal stem cells in treatment if the treatments that have been used so far are no longer effective. On the other hand, the use of mesenchymal stem cells as a treatment has many benefits, one of which is the lack of damage that is usually caused by chemical treatments on the body. The use of mesenchymal stem cells in the treatment of bacterial infections can reduce the spread of antibiotic resistance [50].

3. Conclusion

In conclusion, MSCs are very capable of eliminating bacterial infections. The use of these cells and their antimicrobial products can be a potential alternative to current treatments, while bacterial resistance can be avoided.

Declarations

Author contribution statement

Reza Esfandiyari, Raheleh Halabian, Elham Behzadi, Hamid Sedighian, Ramezan Safari, Abbas Ali Imani Fooladi: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] R.I. Aminov, A brief history of the antibiotic era: lessons learned and challenges for the future, Front. Microbiol. 1 (2010) 134.
[2] C.L. Ventola, The antibiotic resistance crisis: part 1: causes and threats, Pharm. Therapeut. 40 (4) (2015) 277.
[3] J.M. Blair, et al., Molecular mechanisms of antibiotic resistance, Nat. Rev. Microbiol. 13 (1) (2015) 42.
[4] E.F. Haney, S.C. Mansour, R.E. Hancock, Antimicrobial peptides: an introduction. Antimicrobial Peptides, Springer, 2017, pp. 3–22.
[5] A. Krasnodembskaya, et al., Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37, Stem Cells 28 (12) (2010) 2229–2238.
[6] M. Zanetti, The role of cathelicidins in the innate host defenses of mammals, Curr. Issues Mol. Biol. 7 (2) (2005) 179–196.
[7] M. Zanetti, Cathelicidins, multifunctional peptides of the innate immunity, J. Leukoc. Biol. 75 (1) (2004) 39–48.
[8] M. Doss, et al., Human defensins and LL-37 in mucosal immunity, J. Leukoc. Biol. 87 (1) (2010) 79–92.
[9] G.H. Gudmundsson, et al., The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes, Eur. J. Biochem. 238 (2) (1996) 325–332.
[10] S.D. Schwartz, et al., Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degradation and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies, The Lancet 385 (9967) (2015) 509–516.
[11] D.K. Sung, et al., Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta-defensin-2 via toll-like receptor 4 signaling, Cell Microbiol. 18 (3) (2016) 424–436.
[12] G. Chamberlain, et al., Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing, Stem Cells 25 (11) (2007) 2739–2749.
[13] A.M. DiMarino, A.I. Caplan, T.L. Bonfield, Mesenchymal stem cells in tissue repair, Front. Immunol. 4 (2013) 201.
[14] F. Alcaya-Miranda, J. Cuenca, M. Khoury, Antimicrobial activity of mesenchymal stem cell: current status and new perspectives of antimicrobial peptide-based therapies, Front. Immunol. 8 (2017) 239.
[15] P. Storici, et al., Purification and structural characterization of bovine cathelicidins, precursors of antimicrobial peptides, Eur. J. Biochem. 238 (3) (1996) 769–776.
[16] C. Donshar, et al., A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranaesin for enhanced antimicrobial activity and improved pharmacokinetics, Int. J. Antimicrob. Agents 52 (1) (2018) 52–62.
[17] K. Braun, et al., Membrane interactions of mesoporous silica nanoparticles as carriers of antimicrobial peptides, J. Colloid Interface Sci. 475 (2016) 161–170.
[18] B. Agerberth, et al., FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis, Proc. Natl. Acad. Sci. 92 (1) (1995) 195–199.
[19] C.J. Morton, et al., Solution structure and peptide binding of the SH3 domain from human Fyn, Structure 4 (6) (1996) 705–714.
[20] A.M. van der Does, et al., LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature, J. Immunol. (2010) 1000376.
[21] S. Tokunaru, et al., Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37, J. Immunol. 175 (7) (2005) 4662–4668.
[22] J.M. Kahlenberg, M.J. Kaplan, Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease, J. Immunol. 191 (10) (2013) 4905–4901.
[23] R. Koczuła, et al., An angiogenic role for the human peptide antibiotic LL-37/ICAP-18, J. Clin Invest 111 (11) (2003) 1665–1672.
[24] F. Niyonsaba, et al., A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis, Immunology 106 (1) (2002) 20–26.
[25] F. Schieman, et al., The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4, J. Immunol. (2009), 0805587.
[26] Y.J. Hwang, et al., Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis, Mediat. Inflamm. 2014 (2014).
[27] C.I. Chamorro, et al., The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes, J. Investig. Dermatol. 129 (4) (2009) 937–944.
[28] S. Pochet, et al., Modulation by LL-37 of the responses of salivary glands to purinergic agonists, Mol. Pharmacol. (2006).
[29] K.V. Ramana, et al., Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages, J. Biol. Chem. 281 (44) (2006) 33019–33029.
[30] L. Li, et al., New development in studies of formyl-peptide receptors: critical roles in host defense, J. Leukoc. Biol. 93 (3) (2013) 425–435.
[31] Y. Zhao, et al., Curcumin inhibits proliferation of interleukin-22-treated HaCaT cells, Int. J. Clin. Exp. Med. 8 (6) (2015) 9580.
[32] K. Kuroda, et al., The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs, Front. Oncol. 5 (2015) 144.
[33] R.R. Ramos, L. Domingues, F. Gama, LL37, a human antimicrobial peptide with immunomodulatory properties, Sci. Against Microb. Pathogens: Commun. Curr. Res. Technol. Adv. 2 (2011) 915–925.
[34] E. Pandur, et al., α-1 Antitrypsin binds preprohepcidin intracellularly and prohepcidin in the serum, FEBS J. 276 (7) (2009) 2012–2021.
[35] M. Westling-Resnick, Iron homeostasis and the inflammatory response, Annu. Rev. Nutr. 30 (2010) 105–122.
[36] T. Ganz, E. Nemeth, Iron homeostasis in host defence and inflammation, Nat. Rev. Immunol. 15 (8) (2015) 500.
[37] R.L. Mackenzie, K. Iwasaki, Y. Tsuji, Intracellular iron transport and storage: from molecular mechanisms to health implications, Antioxidants Redox Signal. 10 (6) (2008) 997–1030.
[38] M.L.-H. Huang, et al., Heparin bound to α2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels, J. Biol. Chem. 288 (35) (2013) 25450–25465.
[39] J.M. Kim, Antimicrobial proteins in intestine and inflammatory bowel diseases, Intest. Res. 12 (1) (2014) 20–33.
[40] S. Das, et al., Comparative genomics and evolution of the alpha-defensin multigene family in primates, Mol. Biol. Evol. 27 (10) (2010) 2333–2343.
[41] M. Sarabheimo, et al., Increased levels of α-defensin (-1, -2 and -3) in type 1 diabetic patients with nephropathy, Nephrol. Dial. Transplant. 23 (3) (2008) 914–918.
[42] N. Anticheva, P. Guilda, A. Toni, Defensins. Handbook of Biologically Active Peptides, second ed., Elsevier, 2013, pp. 101–118.
[43] C.L. Wohlfeld-Lenane, et al., Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease, J. Virol. 83 (21) (2009) 11385–11390.
[44] Y. Shai, Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides, Biophys. Biophys. Acta Biomembr. 1462 (1-2) (1999) 55–70.
[45] N. Gupta, et al., The TLR4-PAR1 Axis regulates bone marrow mesenchymal stromal cell survival and therapeutic capacity in experimental bacterial pneumonia, Stem Cells 36 (5) (2018) 796–806.
[46] M. Qiao, et al., Review of antibiotic resistance in China and its environment, Environ. Int. 110 (2018) 160–172.
[47] F. Gao, et al., Mesenchymal stem cells and immunomodulation: current status and future prospects, Cell Death Dis. 7 (1) (2016), e2062.
[48] C. Zhu, et al., Antimicrobial design of titanium surface that kill sessile bacteria but support stem cells adhesion, Appl. Surf. Sci. 389 (2016) 7–16.
[49] I. De Domenico, D.M. Ward, J. Kaplan, Heparin regulation: ironing out the details, J. Clin Investig. 117 (7) (2007) 1755–1758.